secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sarepta Therapeutics, Inc. (SRPT)
CIK:        0000873303
Form:       8-K
Filed at:   2021-10-15T23:59:59+00:00
Accession:  0001193125-21-300047
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sarepta prices $500M common stock offering; preliminary Q3 revenue up 37% to $166.9M
--------------------------------------------------------------------------------

- Preliminary Q3 2021 net product revenue of ~$166.9M, up from $121.4M in Q3 2020.
- Cash, cash equivalents and investments were ~$1.6B as of Sept 30, 2021, down from $1.9B at Dec 31, 2020.
- Priced public offering of 6,172,840 shares at $81.00/share for gross proceeds of $500M; net proceeds ~$549.1M.
- Underwriters granted 30-day option for additional 925,926 shares, exercised in full; closing expected Oct 18, 2021.
- Proceeds to fund clinical trials, commercialization, manufacturing, and potential acquisitions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/873303/000119312521300047/0001193125-21-300047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/873303/000119312521300047/d228298d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-300047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer